Larimar Therapeutics (LRMR) Other Non Operating Income (2013 - 2020)
Larimar Therapeutics' (LRMR) quarterly Other Non Operating Income came in at $218000.0 in Q1 2020, up 847.83% on a YoY basis from $23000.0 in Q2 2019, and up 282.46% quarter-over-quarter from $57000.0 in Q4 2019.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Other Non Operating Income (2013 - 2020) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Other Non Operating Income for 8 consecutive years, with $218000.0 the latest figure, recorded in Q1 2020.
- For the quarter ending Q1 2020, Other Non Operating Income rose 847.83% year-over-year to $218000.0; the trailing twelve-month figure through Mar 2020 stood at $220000.0 (up 245.7% YoY), and the FY2019 full-year result was $25000.0, up 110.55% from the prior year.
- Other Non Operating Income rose to $218000.0 in Q1 2020 per LRMR's latest filing, from $57000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $218000.0 in Q1 2020 and bottomed at -$97000.0 in Q4 2016.
- Historically, Other Non Operating Income has averaged $7529.4 across 5 years, with a median of -$5000.0 in 2017.
- The sharpest annual moves came in 2016 and 2020: Other Non Operating Income tumbled 1375.0% in 2016, then jumped 847.83% in 2020.
- Over 5 years, Other Non Operating Income stood at -$97000.0 in 2016, then soared by 125.77% to $25000.0 in 2017, then tumbled by 320.0% to -$55000.0 in 2018, then soared by 203.64% to $57000.0 in 2019, then surged by 282.46% to $218000.0 in 2020.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $218000.0, $57000.0, and -$33000.0 for Q1 2020, Q4 2019, and Q3 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 218,000.00 |
| Dec 31, 2019 | 57,000.00 |
| Sep 30, 2019 | -33,000.00 |
| Jun 30, 2019 | -22,000.00 |
| Mar 31, 2019 | 23,000.00 |
| Dec 31, 2018 | -55,000.00 |
| Sep 30, 2018 | -46,000.00 |
| Jun 30, 2018 | -73,000.00 |
| Mar 31, 2018 | -63,000.00 |
| Dec 31, 2017 | 25,000.00 |
| Sep 30, 2017 | 20,000.00 |
| Jun 30, 2017 | -5,000.00 |
| Mar 31, 2017 | 100,000.00 |
| Dec 31, 2016 | -97,000.00 |
| Sep 30, 2016 | 58,000.00 |
| Jun 30, 2016 | -51,000.00 |
| Mar 31, 2016 | 72,000.00 |
| Dec 31, 2015 | 59,000.00 |
| Sep 30, 2015 | -110,000.00 |
| Jun 30, 2015 | 4,000.00 |